MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY

PROVIDED HEREIN ARE HETEROARYL COMPOUNDS HAVING THE FOLLOWING STRUCTURE: R2N (Ι) OR (ΙΙ) WHEREIN R1 - R4 ARE AS DEFINED HEREIN, COMPOSITIONS COMPRISING AN EFFECTIVE AMOUNT OF A HETEROARYL COMPOUND AND METHODS FOR TREATING OR PREVENTING CANCER, INFLAMMATORY CONDITIONS, IMMUNOLOGICAL CONDITIONS, NEURO...

Full description

Saved in:
Bibliographic Details
Main Authors JINGJING ZHAO, JAN ELSNER, JOHN SAPIENZA, DEBORAH MORTENSEN, SABITA SANKAR, LIDA TEHRANI, KIMBERLY FULTZ, SOPHIE PERRIN-NINKOVIC, JASON PARNES, RAMA K. NARLA, GARRICK PACKARD, WEIMING XU, PATRICK PAPA, BRANDEN LEE, ROY L.HARRIS, GRAZIELLA SHEVLIN, JENNIFER RIGGS, LOUI MADAKAMUTIL
Format Patent
LanguageEnglish
Published 30.12.2016
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:PROVIDED HEREIN ARE HETEROARYL COMPOUNDS HAVING THE FOLLOWING STRUCTURE: R2N (Ι) OR (ΙΙ) WHEREIN R1 - R4 ARE AS DEFINED HEREIN, COMPOSITIONS COMPRISING AN EFFECTIVE AMOUNT OF A HETEROARYL COMPOUND AND METHODS FOR TREATING OR PREVENTING CANCER, INFLAMMATORY CONDITIONS, IMMUNOLOGICAL CONDITIONS, NEURODEGENERATIVE DISEASES, DIABETES, OBESITY, NEUROLOGICAL DISORDERS, AGE-RELATED DISEASES, OR CARDIOVASCULAR CONDITIONS, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF A HETEROARYL COMPOUND TO A PATIENT IN NEED THEREOF.
Bibliography:Application Number: MY2011PI01855